CD8A and esophageal squamous cell carcinoma: In a clinical study, preventive anti‐PD‐1 antibody treatment increased CD8+ TRM cell infiltration into the immune microenvironment for an extended period and provided long‐term benefits to patients with ESCC.135, 242